- News & Events
- Contact Us
|View printer-friendly version|
|Amgen Announces Launch Of Blood Counts™ And Collaboration With StoryCorps To Record And Share Stories Of Those Impacted By Multiple Myeloma|
"The 'telling of stories' goes back thousands of years, and most of us have memories of being told a story and listening with rapt attention. It takes us to another place," said
Storytelling can be a helpful way for people to cope with cancer.1 In addition to showing effects in four areas – cognitive, affective, interpersonal and personal – hearing others' stories can also provide hope for cancer patients and their families.1 In 2017, Blood Counts will continue to record additional conversations from the multiple myeloma community. Those interested in sharing their personal experience or work in the field are encouraged to sign up to participate at www.BloodCounts.com.
"StoryCorps gives everyday people, including those who are facing serious illness, the opportunity to record meaningful conversations about who they are, what they've learned in life, and what matters most to them. We share these stories to build compassion and offer hope to others," said
Multiple myeloma is an incurable blood cancer characterized by a recurring pattern of remission and relapse.2 Each patient's journey is different and will often require different approaches over time, but what remains the biggest hurdle is the ongoing cycle of success and failure in therapy.2 Lack of awareness around multiple myeloma can lead to delayed diagnoses, which can have a significant impact on the clinical course of the disease.3
"Over the past decade, we have seen significant advances in treating multiple myeloma, which have made a difference in the lives of those impacted by the disease,"2 said
"Blood Counts is important as it gives the multiple myeloma community a platform to raise awareness of this incurable disease through the power of storytelling," said
About Blood Counts
Forward Looking Statements
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. We are increasingly dependent on information technology systems, infrastructure and data security. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amgen-announces-launch-of-blood-counts-and-collaboration-with-storycorps-to-record-and-share-stories-of-those-impacted-by-multiple-myeloma-300372331.html